Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2022-04-05

FDA Approved: IBSRELA — Supplemental Application (Ardelyx, Inc.)

View source ↗

Summary

FDA approved a supplemental application for IBSRELA (tenapanor hydrochloride) submitted by Ardelyx, updating the drug labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBSRELA (tenapanor hydrochloride)

Snippet

SUPPL AP for IBSRELA (TENAPANOR HYDROCHLORIDE)